Higher demand for its specialty medicines business offset a decline of Arexvy sales for respiratory syncytial virus and sales of Shingrix for shingles in the U.S. U.S. health officials in June ...

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...

A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged ...

Of the RSV patients aged 60 or older, 23.0% were admitted to an ICU, 31.5% had acute organ failure, and 9.8% received IMV or ...

PHILADELPHIA, PA — The Advisory Committee on Immunization Practices (ACIP) has voted to expand the recommended use of GSK’s AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults ...

The study was a phase 3 clinical trial on GSK’s Arexvy vaccine, which was published April 14 in The Lancet Respiratory Medicine. The findings were the first that tracked vaccine efficacy over ...

GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s for whom it is approved.

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

Vaccine sales fell 6% to 2.1 billion pounds, with its newer RSV shot Arexvy bringing in just 0.1 billion pounds, down 57%. The company is a "bit cautious in the current environment" on the outlook ...

AREXVY is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are ...